Free Trial

Eddie Hickman Analyst Performance

Analyst at Guggenheim

Eddie Hickman is a stock analyst at Guggenheim, covering 5 publicly traded companies across a range of sectors. Over the past year, Eddie Hickman has issued 9 stock ratings, including buy and hold recommendations. While full access to Eddie Hickman's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eddie Hickman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 0 Years
Buy Recommendations
88.89% 8 Buy Ratings
Companies Covered
5 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy88.9%8 ratings
Hold11.1%1 ratings
Sell0.0%0 ratings

Out of 9 total stock ratings issued by Eddie Hickman at Guggenheim, the majority (88.9%) have been Buy recommendations, followed by 11.1% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
80.0% of companies on NASDAQ
4 companies
NYSE
20.0% of companies on NYSE
1 company

Eddie Hickman, an analyst at Guggenheim, currently covers 5 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
5 companies
100.0%

Eddie Hickman of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
80.0%
PHARMACEUTICAL PREPARATIONS
1 company
20.0%

Eddie Hickman's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/28/2025Downgrade$1.10Neutral
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5/2/2025Boost Price Target$48.54$84.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
4/1/2025Reiterated Rating$0.73$6.00Buy
Cybin Inc. stock logo
CYBN
Cybin
3/13/2025Initiated Coverage$7.34$35.00Buy
GH Research PLC stock logo
GHRS
GH Research
3/13/2025Initiated Coverage$11.35$32.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
2/26/2025Reiterated Rating$0.72Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/24/2025Reiterated Rating$46.72$78.00Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/10/2025Reiterated Rating$52.48Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1/17/2025Reiterated Rating$2.19$12.00Buy